Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,108 public trials 2,040 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

NCT02112526

Conditions
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site New York, United States
  • Research Site Columbus, Ohio, United States
View Trial Details
Completed

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

NCT01903811

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +18 more
Locations
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • The University of Arizona Medical Center-University Campus Tucson, Arizona, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
View all 485 locations
View Trial Details
Completed

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05008055

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Los Angeles, California, United States
  • Research Site Houston, Texas, United States
  • Research Site Victoria, British Columbia, Canada
View all 17 locations
View Trial Details
Completed

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

NCT03677141

Conditions
B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • University of California; Moores Cancer Center La Jolla, California, United States
  • University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica Santa Monica, California, United States
View all 41 locations
View Trial Details

Related conditions